Imagine a gym membership where the trainer knows exactly how your body reacts to cancer treatment and guides you through a screen at home. Instead of a one-size-fits-all workout, the program changes based on whether you are struggling with fatigue or nerve pain. It's like having a specialized medical coach in your living room to help you get your strength and quality of life back.
Cancer survivors face long-term side effects that reduce productivity and quality of life, but current exercise interventions are inaccessible due to travel constraints and a lack of tailored care.
A modular, home-based exercise intervention system with live-remote supervision and a professional education module for healthcare workers.
If you are a telemedicine platform provider dealing with low patient engagement in recovery programs — this project developed a live-remote supervision model that improves accessibility. By using a modular design tailored to specific side effects, you can increase user retention and health outcomes.
If you are a private oncology clinic dealing with limited physical space for rehabilitation — this project developed a home-based exercise intervention with remote supervision. This allows you to support more survivors without needing more square footage in your facility.
If you are a health insurance provider dealing with high long-term care costs for cancer survivors — this project developed a cost-effective exercise intervention. By improving productivity and functioning for survivors, you can potentially reduce long-term disability claims.
Based on available project data, the project aims to demonstrate cost-effectiveness, but specific pricing or implementation costs are not provided.
The project uses a national broadcast centre for live-remote supervision, suggesting a scalable model for wide distribution across a population.
Based on available project data, there is no mention of specific patents or licensing agreements; the focus is on guideline recommendations and education modules.
The project includes extensive ethical, legal, and social impact components to identify barriers and provide policy recommendations for implementation.
The project period runs from 2022-11-01 to 2027-10-31, indicating it is currently in the execution phase.
The consortium is research-heavy with 11 academic and research entities (5 universities, 6 research organizations) and 3 other partners. With a 14% industry ratio (2 industry partners, 1 of which is an SME), the project is primarily driven by clinical validation rather than immediate commercial product development, though the inclusion of industry suggests a path toward market translation.
Contact the Universitaire Medisch Centrum Utrecht for clinical trial results and implementation guidelines.
Contact us to connect with the PREFERABLE-II consortium for licensing the remote supervision model.
